Innate Pharma S.A. ADR (IPHA)

$2.07 -0.19 (-8.41%)
Market Cap 212.26M
Revenue (ttm) 10.19M
Net Income (ttm) -55.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -546.03%
Debt to Equity Ratio -1.04
Volume 46,400
Avg Vol 181,806
Day's Range N/A - N/A
Shares Out 93.92M
Stochastic %K 42%
Beta 0.33
Analysts Strong Sell
Price Target $6.67

Company Profile

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
Address:
117, Avenue de Luminy, BP 30191, Marseille, France
Dizzy8
Dizzy8 Aug. 14 at 8:23 PM
$IPHA Laughing all the way to the bank
0 · Reply
focafoca99
focafoca99 Aug. 14 at 10:21 AM
$IPHA scheduled a conference call and webcast for August 14.
0 · Reply
Zephix
Zephix Aug. 13 at 8:55 PM
$IPHA jeep17
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 13 at 1:38 PM
$IPHA “The average 12-month analyst price target for Innate Pharma (NASDAQ: IPHA) is approximately $6.67, with forecasts ranging from a low of $3.00 to a high of $9.00. Recent updates include BTIG Research raising its target to $9.00 and HC Wainwright & Co. raising its target to $7.00.”
0 · Reply
topstockalerts
topstockalerts Aug. 12 at 8:08 PM
$IPHA I wasn’t interested earlier. That’s changing.
0 · Reply
prismmarketview
prismmarketview Aug. 12 at 4:29 PM
$DOGZ and $GRWG are today’s standouts. $DOGZ +38.72% with massive volume at roughly 37.1M shares. $GRWG +26.84% after Q2 net sales rose 5.5% year over year to $43.2M and gross margin improved to 28.5%. Also active: $INBS +19%, $IPHA +16%, $SNAL -32%. Stock prices and percentage changes are as of 12:15 p.m. ET on August 12, 2026, and are subject to change. https://prismmarketview.com/prism-mid-day-movers-pet-care-and-cannabis-are-todays-leaders/
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:17 PM
$IPHA “Innate Pharma’s Chief Medical Officer joining a bladder cancer panel at the BTIG Virtual Biotechnology Conference keeps IPH4502 and the broader pipeline in front of the right audience. When a small‑cap like IPHA stands next to names like AstraZeneca and Sanofi in the same conversation, it reinforces the story traders are buying: this is a real oncology player, not just a lab slide.” 📈🔥👍
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:10 PM
$IPHA BTIG analyst Jeet Mukherjee raised Innate Pharma S.A.'s price target to $9.00 from $8.00 and maintained a Buy rating. This update follows Innate Pharma's recent clinical progress on IPH4502 and corporate participation in BTIG's virtual biotechnology investor panels.
1 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:04 PM
$IPHA IN 😎📈🔥👍
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 12 at 1:46 PM
$OFAL now towards 400%. $BIVI New high of day $GRWG Trend $IPHA new high $XHLD Continuation
1 · Reply
Latest News on IPHA
Innate Pharma price target raised to $9 from $8 at BTIG

2026-08-17T09:57:03.000Z - 2 days ago

Innate Pharma price target raised to $9 from $8 at BTIG

Innate Pharma SA To Hold Conference Call Transcript

2026-08-14T21:01:17.000Z - 4 days ago

Innate Pharma SA To Hold Conference Call Transcript

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Fri, 14 Aug 2026 15:03:16 -0400 - 4 days ago

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma Transcript: Investor update

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Innate Pharma Transcript: Investor update

Innate Pharma Press release: Investor update

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Innate Pharma Press release: Investor update

Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast

2026-08-14T09:36:00.000Z - 5 days ago

Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast

Innate Pharma Announces Conference Call and Webcast

Fri, 14 Aug 2026 05:30:00 -0400 - 5 days ago

Innate Pharma Announces Conference Call and Webcast

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

2026-08-14T08:27:00.000Z - 5 days ago

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

Innate Pharma Slides: Company presentation

Aug 14, 2026, 2:00 AM EDT - 5 days ago

Innate Pharma Slides: Company presentation

Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares

2026-08-13T20:06:00.000Z - 5 days ago

Innate Pharma SA: Innate Pharma Announces Proposed Offering of Ordinary Shares

Leerink upgrades Innate Pharma to Outperform after lacutamab deal

2026-08-11T10:20:22.000Z - 8 days ago

Leerink upgrades Innate Pharma to Outperform after lacutamab deal

IPHA

Innate Pharma upgraded to Outperform from Market Perform at Leerink

2026-08-11T10:15:44.000Z - 8 days ago

Innate Pharma upgraded to Outperform from Market Perform at Leerink

IPHA

Innate Pharma price target raised to $7 from $5 at H.C. Wainwright

2026-08-10T16:30:11.000Z - 8 days ago

Innate Pharma price target raised to $7 from $5 at H.C. Wainwright

IPHA

Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO

2026-08-10T10:21:29.000Z - 9 days ago

Innate Pharma Jumps After Sobi Deal To Advance Lacutamab Into Phase 3; Appoints Markus Jensen As CMO

Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study

2026-08-10T09:30:47.000Z - 9 days ago

Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study

IPHA

Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed

2026-08-10T09:30:37.000Z - 9 days ago

Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed

IPHA

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

2026-08-10T07:10:24.000Z - 9 days ago

Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma

Swedish Orphan Biovitrum AB: Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

2026-08-10T06:42:00.000Z - 9 days ago

Swedish Orphan Biovitrum AB: Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Innate Pharma SA: Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

2026-08-10T06:36:00.000Z - 9 days ago

Innate Pharma SA: Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Aug 10, 2026, 2:32 AM EDT - 9 days ago

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

IPHA

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Aug 10, 2026, 2:30 AM EDT - 9 days ago

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

IPHA

Innate Pharma SA: Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

2026-08-10T06:06:00.000Z - 9 days ago

Innate Pharma SA: Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Aug 10, 2026, 2:00 AM EDT - 9 days ago

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

IPHA

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

2026-08-10T06:00:00.000Z - 9 days ago

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

Innate Pharma SA: Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

2026-07-23T05:06:00.000Z - 27 days ago

Innate Pharma SA: Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

Jul 23, 2026, 1:00 AM EDT - 27 days ago

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

IPHA

Innate Pharma (IPHA) Completes Enrollment for Phase 1 Study of IPH4502

2026-07-21T10:51:14.000Z - 4 weeks ago

Innate Pharma (IPHA) Completes Enrollment for Phase 1 Study of IPH4502

Innate Pharma completes enrollment in dose escalation of IPH4502 study

2026-07-21T09:30:20.000Z - 4 weeks ago

Innate Pharma completes enrollment in dose escalation of IPH4502 study

IPHA

Innate Pharma SA: Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

2026-07-21T05:06:00.000Z - 4 weeks ago

Innate Pharma SA: Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

Jul 21, 2026, 1:00 AM EDT - 4 weeks ago

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

IPHA

Innate Pharma Slides: Corporate presentation

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Innate Pharma Slides: Corporate presentation

Outcome of Innate Pharma's 2026 Annual General Meeting

May 22, 2026, 1:00 AM EDT - 3 months ago

Outcome of Innate Pharma's 2026 Annual General Meeting

IPHA

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026, 1:00 AM EDT - 3 months ago

Innate Pharma to participate in the Jefferies Global Healthcare Conference

IPHA

Innate Pharma Q1 Earnings Call Highlights

Wed, 13 May 2026 12:07:58 -0400 - 3 months ago

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma Earnings Call Transcript: Q1 2026

May 13, 2026, 7:30 AM EDT - 3 months ago

Innate Pharma Earnings Call Transcript: Q1 2026

Innate Pharma Earnings release: Q1 2026

May 13, 2026, 7:30 AM EDT - 3 months ago

Innate Pharma Earnings release: Q1 2026

Innate Pharma Slides: Q1 2026

May 13, 2026, 7:30 AM EDT - 3 months ago

Innate Pharma Slides: Q1 2026

Innate Pharma Earnings release: Q1 2026

May 13, 2026, 7:30 AM EDT - 3 months ago

Innate Pharma Earnings release: Q1 2026

Innate Pharma Slides: Corporate presentation

May 13, 2026, 2:00 AM EDT - 3 months ago

Innate Pharma Slides: Corporate presentation

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026, 1:00 AM EDT - 3 months ago

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

IPHA

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

May 12, 2026, 1:00 AM EDT - 3 months ago

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

IPHA

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

May 6, 2026, 1:00 AM EDT - 3 months ago

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

IPHA

Innate Pharma to Participate in the D. Boral Capital Global Conference

Apr 23, 2026, 1:00 AM EDT - 4 months ago

Innate Pharma to Participate in the D. Boral Capital Global Conference

IPHA

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

Apr 17, 2026, 3:00 PM EDT - 4 months ago

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

IPHA

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

Apr 13, 2026, 1:00 AM EDT - 4 months ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026

IPHA

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

Apr 13, 2026, 1:00 AM EDT - 4 months ago

Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

IPHA

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

Apr 8, 2026, 1:00 AM EDT - 4 months ago

Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

IPHA

Innate Pharma to Participate in the Kempen Life Sciences Conference

Apr 3, 2026, 1:00 AM EDT - 4 months ago

Innate Pharma to Participate in the Kempen Life Sciences Conference

IPHA

Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report

Apr 2, 2026, 4:00 AM EDT - 4 months ago

Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report

IPHA

Innate Pharma Earnings Call Transcript: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Earnings Call Transcript: Q4 2025

Innate Pharma Annual report: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Annual report: Q4 2025

Innate Pharma Earnings release: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Earnings release: Q4 2025

Innate Pharma Earnings release: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Earnings release: Q4 2025

Innate Pharma Slides: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Slides: Q4 2025

Innate Pharma Annual report: Q4 2025

Mar 26, 2026, 9:00 AM EDT - 5 months ago

Innate Pharma Annual report: Q4 2025

Innate Pharma Slides: Corporate presentation

Mar 26, 2026, 3:00 AM EDT - 5 months ago

Innate Pharma Slides: Corporate presentation

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

Thu, 26 Mar 2026 02:00:00 -0400 - 5 months ago

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

Thu, 19 Mar 2026 02:00:00 -0400 - 5 months ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

Innate Pharma assumed with a Buy at BTIG

2026-03-11T20:28:46.000Z - 5 months ago

Innate Pharma assumed with a Buy at BTIG

IPHA

Innate Pharma Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:40 PM EDT - 5 months ago

Innate Pharma Transcript: Leerink Global Healthcare Conference 2026

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

Thu, 19 Feb 2026 01:00:00 -0500 - 6 months ago

Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026

Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

Wed, 18 Feb 2026 01:00:00 -0500 - 6 months ago

Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

Wed, 07 Jan 2026 01:00:00 -0500 - 8 months ago

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Mon, 22 Dec 2025 01:00:00 -0500 - 8 months ago

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

Innate Pharma Slides: Corporate presentation

Dec 18, 2025, 2:30 AM EST - 8 months ago

Innate Pharma Slides: Corporate presentation

Innate Pharma Releases Its 2026 Financial Calendar

Thu, 11 Dec 2025 01:00:00 -0500 - 8 months ago

Innate Pharma Releases Its 2026 Financial Calendar

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Fri, 28 Nov 2025 01:00:00 -0500 - 9 months ago

Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025

Innate Pharma Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 9:30 AM EST - 9 months ago

Innate Pharma Transcript: Jefferies London Healthcare Conference 2025

Innate Pharma to Present at Jefferies Global Healthcare Conference

Mon, 17 Nov 2025 01:00:00 -0500 - 9 months ago

Innate Pharma to Present at Jefferies Global Healthcare Conference

Innate Pharma Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Innate Pharma Earnings Call Transcript: Q3 2025

Innate Pharma Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Innate Pharma Earnings release: Q3 2025

Innate Pharma Earnings release: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Innate Pharma Earnings release: Q3 2025

Innate Pharma Slides: Q3 2025

Nov 13, 2025, 8:00 AM EST - 9 months ago

Innate Pharma Slides: Q3 2025

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

Nov 13, 2025, 1:00 AM EST - 9 months ago

Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results

IPHA

Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial

2025-11-10T11:00:27.000Z - 10 months ago

Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial

IPHA

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

Nov 10, 2025, 1:00 AM EST - 10 months ago

Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL

IPHA

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

Nov 5, 2025, 1:00 AM EST - 10 months ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates

IPHA

Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright

2025-10-29T10:10:27.000Z - 10 months ago

Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright

IPHA

Innate Pharma Transcript: Investor Update

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Innate Pharma Transcript: Investor Update

Innate Pharma Slides: Investor Update

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Innate Pharma Slides: Investor Update

Innate Pharma initiated with a Buy at Lucid Capital

2025-10-23T11:20:13.000Z - 10 months ago

Innate Pharma initiated with a Buy at Lucid Capital

IPHA

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

Oct 14, 2025, 1:00 AM EDT - 11 months ago

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

IPHA

Innate Pharma management to meet with BTIG

2025-10-02T16:45:09.000Z - 11 months ago

Innate Pharma management to meet with BTIG

IPHA

Innate Pharma management to meet with BTIG

2025-09-30T16:25:18.000Z - 11 months ago

Innate Pharma management to meet with BTIG

IPHA

Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright

2025-09-18T10:05:36.000Z - 11 months ago

Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright

IPHA

Innate Pharma downgraded to Market Perform from Outperform at Leerink

2025-09-17T22:40:14.000Z - 11 months ago

Innate Pharma downgraded to Market Perform from Outperform at Leerink

IPHA

Innate Pharma Earnings Call Transcript: Q2 2025

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings Call Transcript: Q2 2025

Innate Pharma Earnings release: Q2 2025

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings release: Q2 2025

Innate Pharma Quarterly report: Q2 2025

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Quarterly report: Q2 2025

Innate Pharma Earnings release: Q2 2025

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings release: Q2 2025

Innate Pharma Slides: Q2 2025

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Slides: Q2 2025

Innate Pharma Reports First Half 2025 Business Update and Financial Results

Sep 17, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Reports First Half 2025 Business Update and Financial Results

IPHA

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Sep 15, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

IPHA

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

Sep 10, 2025, 4:30 AM EDT - 1 year ago

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

IPHA

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

Jul 29, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

IPHA

Innate Pharma initiated with a Buy at BTIG

2025-07-28T10:15:44.000Z - 1 year ago

Innate Pharma initiated with a Buy at BTIG

IPHA

Innate Pharma Slides: Corporate Presentation

Jun 20, 2025, 2:30 AM EDT - 1 year ago

Innate Pharma Slides: Corporate Presentation

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Jun 17, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

IPHA

Innate Pharma presents preclinical data for IPH6501 at EHA

2025-06-13T09:15:26.000Z - 1 year ago

Innate Pharma presents preclinical data for IPH6501 at EHA

IPHA

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Jun 13, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

IPHA

Innate Pharma Transcript: Jefferies Global Healthcare Conference

Jun 5, 2025, 8:10 AM EDT - 1 year ago

Innate Pharma Transcript: Jefferies Global Healthcare Conference

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

IPHA

Innate Pharma presents long-term follow-up data from TELLOMAK trial

2025-05-23T09:15:31.000Z - 1 year ago

Innate Pharma presents long-term follow-up data from TELLOMAK trial

IPHA

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

May 23, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

IPHA

Outcome of Innate Pharma's 2025 Annual General Meeting

May 23, 2025, 1:00 AM EDT - 1 year ago

Outcome of Innate Pharma's 2025 Annual General Meeting

IPHA

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

May 19, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

IPHA

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

May 15, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

IPHA

Innate Pharma Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings Call Transcript: Q1 2025

Innate Pharma Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings release: Q1 2025

Innate Pharma Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Earnings release: Q1 2025

Innate Pharma Slides: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Innate Pharma Slides: Q1 2025

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

May 13, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results

IPHA

Innate Pharma announces conference call and webcast for Q1 2025 business update

May 6, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma announces conference call and webcast for Q1 2025 business update

IPHA

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

Apr 30, 2025, 11:30 AM EDT - 1 year ago

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F

IPHA

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

Apr 29, 2025, 3:00 PM EDT - 1 year ago

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting

IPHA

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

2025-04-24T10:12:11.000Z - 1 year ago

Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright

IPHA

Innate Pharma Announces €15M Investment by Sanofi

Apr 24, 2025, 1:35 AM EDT - 1 year ago

Innate Pharma Announces €15M Investment by Sanofi

IPHA

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Apr 23, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

IPHA

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Apr 16, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

IPHA

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

Apr 16, 2025, 1:00 AM EDT - 1 year ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025

IPHA

Dizzy8
Dizzy8 Aug. 14 at 8:23 PM
$IPHA Laughing all the way to the bank
0 · Reply
focafoca99
focafoca99 Aug. 14 at 10:21 AM
$IPHA scheduled a conference call and webcast for August 14.
0 · Reply
Zephix
Zephix Aug. 13 at 8:55 PM
$IPHA jeep17
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 13 at 1:38 PM
$IPHA “The average 12-month analyst price target for Innate Pharma (NASDAQ: IPHA) is approximately $6.67, with forecasts ranging from a low of $3.00 to a high of $9.00. Recent updates include BTIG Research raising its target to $9.00 and HC Wainwright & Co. raising its target to $7.00.”
0 · Reply
topstockalerts
topstockalerts Aug. 12 at 8:08 PM
$IPHA I wasn’t interested earlier. That’s changing.
0 · Reply
prismmarketview
prismmarketview Aug. 12 at 4:29 PM
$DOGZ and $GRWG are today’s standouts. $DOGZ +38.72% with massive volume at roughly 37.1M shares. $GRWG +26.84% after Q2 net sales rose 5.5% year over year to $43.2M and gross margin improved to 28.5%. Also active: $INBS +19%, $IPHA +16%, $SNAL -32%. Stock prices and percentage changes are as of 12:15 p.m. ET on August 12, 2026, and are subject to change. https://prismmarketview.com/prism-mid-day-movers-pet-care-and-cannabis-are-todays-leaders/
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:17 PM
$IPHA “Innate Pharma’s Chief Medical Officer joining a bladder cancer panel at the BTIG Virtual Biotechnology Conference keeps IPH4502 and the broader pipeline in front of the right audience. When a small‑cap like IPHA stands next to names like AstraZeneca and Sanofi in the same conversation, it reinforces the story traders are buying: this is a real oncology player, not just a lab slide.” 📈🔥👍
0 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:10 PM
$IPHA BTIG analyst Jeet Mukherjee raised Innate Pharma S.A.'s price target to $9.00 from $8.00 and maintained a Buy rating. This update follows Innate Pharma's recent clinical progress on IPH4502 and corporate participation in BTIG's virtual biotechnology investor panels.
1 · Reply
TrendIsMyFriend
TrendIsMyFriend Aug. 12 at 2:04 PM
$IPHA IN 😎📈🔥👍
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 12 at 1:46 PM
$OFAL now towards 400%. $BIVI New high of day $GRWG Trend $IPHA new high $XHLD Continuation
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Aug. 11 at 3:36 PM
$CMMB - $40M upfront for $MREO to enter a ph3. MREO has been trying to close a deal for at least 3 years - $75M upfront fo $IPHA. IPHA at least 1.5-2 years looking for a deal. CMMB shareholders get a $40M CVR for getting nebokitug to ph3 for PSC. It's CMMB's turn!
2 · Reply
Naaman12
Naaman12 Aug. 11 at 1:20 PM
$STKH $IPHA
0 · Reply
Emroy
Emroy Aug. 11 at 10:07 AM
$IPHA
0 · Reply
SDBiotechInvestor
SDBiotechInvestor Aug. 10 at 6:08 PM
$CMMB $IPHA - Obviously beating a dead horse on this, but fact $IPHA got significant funding for a much smaller Rare disease indication bodes very well for a $CMMB PSC outlicense.
1 · Reply
Kevin73ca
Kevin73ca Aug. 10 at 5:04 PM
$IPHA 52 week high soon
0 · Reply
prismmarketview
prismmarketview Aug. 10 at 4:18 PM
PRISM Mid-Day Movers: New Energy and Global Health are Today’s Leaders. 5E Advanced Materials, Inc. (NASDAQ: $FEAM ) is surging today, with the stock up about 40% from Friday’s 1.50 close as buyers pile into the boron‑materials developer. Silence Therapeutics plc (NASDAQ: $SLN ) is surging today, with the stock up roughly 34% to 16.13 after closing at 11.95 on Friday. Other Notable Movers: Innate Pharma S.A. ( $IPHA) up 24% AgEagle Aerial Systems, Inc. ( $UAVS) up 16% Vertical Aerospace Ltd. ( $EVTL ) down -34% https://prismmarketview.com/prism-mid-day-movers-new-energy-and-global-health-are-todays-leaders/
0 · Reply
Emroy
Emroy Aug. 10 at 3:22 PM
$IPHA 👁️
0 · Reply
smallcapexpert
smallcapexpert Aug. 10 at 2:29 PM
$IPHA 3$ in a few weeks. 📈 will add to 100k📈
0 · Reply
smallcapexpert
smallcapexpert Aug. 10 at 2:01 PM
$IPHA im in 2,16$ avg 40k
0 · Reply
Naaman12
Naaman12 Aug. 10 at 1:49 PM
$STKH RUN FAST AS YOU CAN THIS IS SCAM THEY GONA SELL IT ON YOUR HEAD !!! GO TO IPHA $IPHA
1 · Reply
npcpaperboy
npcpaperboy Aug. 10 at 1:41 PM
$IPHA let's go
0 · Reply
Naaman12
Naaman12 Aug. 10 at 1:38 PM
$SCKT $AUUD $STKH YOU GUYS DOING MISTAKE EVRY TIME GO BUY $IPHA
0 · Reply